PET and SPECT imaging of the NMDA receptor system: An overview of radiotracer development

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 9, 2010, Pages 870-886

  Sobrio, F ^a,b   Gilbert, G ^a,b   Perrio, C ^a,b   Barre L ^a,b   Debruyne, D ^a,b  

^a DIF   (France)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

Imaging; NMDA receptors; PET; Radiopharmaceutical; Radiotracer; SPECT

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RADIOPHARMACEUTICAL AGENT;

CHEMISTRY; DIAGNOSTIC USE; EPILEPSY; HUMAN; ISOTOPE LABELING; METABOLISM; NERVOUS SYSTEM DISEASES; POSITRON EMISSION TOMOGRAPHY; SCHIZOPHRENIA; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EPILEPSY; HUMANS; ISOTOPE LABELING; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77956575790     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791608299     Document Type: Article

References (137)

1. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S.F. The glutamate receptor ion channels. Pharmacol. Rev., 1999, 51, 7-61
2. Paoletti, P.; Neyton, J. NMDA receptor subunits, function and pharmacology. Curr. Opin. Pharmacol., 2007, 7, 39-47.
3. [3] Cull-Candy, S.G.; Leszkiewicz, D.N. Role of distinct NMDA receptor subtypes at central synapses. Sci STKE, 2004, 255,:re16
4. Yamakura, T.; Shimoji, K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog.Neurobiol., 1999, 59, 279-298.
5. Kalia, L.; Kalia, S.; Salter, M. NMDA receptors in clinical neurology, excitatory times ahead. Lancet Neurol., 2008, 7, 742-755
6. Bliss, T.; Collingridge, G. A synaptic model of memory, long-term potentiation in the hippocampus. Nature, 1993, 361, 31-39
7. Loftis, J.M.; Janowsky, A. The N-methyl-D-aspartate receptorsubunit NR2B, localization, functional propertieregulation, andclinical implication. Pharmacol. Ther., 2003, 97, 55-85.
8. Meldrum, B.; Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci., 1990, 11,379-387.
9. Childers, W.E.Jr.; Baudy, R.B. N-methyl-D-aspartate antagonists and neuropathic pain: the search for relief. J. Med. Chem., 2007,50, 2557-2562.
10. Laube, B.; Kuhse, J.; Betz, H. Evidence for a tetrameric structure of recombinant NMDA receptors. J. Neurosci., 1998, 18, 2954-2961.
11. Masuko, T.; Kashiwagi, K.; Kuno, T.; Nguyen, N.D.; Pahk, A.J.;Fukuchi, J.; Igarashi, K.; Williams, K. A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor:effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valinebinding protein. Mol.Pharmacol., 1999, 55, 957-969.
12. Paoletti, P.; Perin-Dureau, F.; Fayyazuddin, A.; Le Goff, A.; Callebaut, I.; Neyton, J. Molecular organization of a zinc binding n-terminal modulatory domain in a NMDA receptor subunit. Neuron,2000, 28, 911-925.
13. Marinelli, L.; Cosconati, S.; Steinbrecher, T.; Limongelli, V.; Bertamino, A.; Novellino, E.; Case, D.A. Homology modeling of NR2B modulatory domain of NMDA receptor and analysis of ifenprodil binding. ChemMedChem, 2007, 2, 1498-1510.
14. Meddows, E.; Le Bourdelles, B.; Grimwood, S.; Wafford, K.;Sandhu, S.; Whiting, P.; McIlhinney, R.A. Identification of molecular determinants that are important in the assembly of N-methyl-D-aspartate receptors. J. Biol. Chem., 2001, 276, 18795-18803.
15. Kew, J.N.; Kemp, J.A. Ionotropic and metabotropic glutamatereceptor structure and pharmacology. Psychopharmacology, 2005,179, 4-29.
16. Kashiwagi, K.; Masuko, T.; Nguyen, C.D.; Kuno, T.; Tanaka, I.;Igarashi, K.; Williams, K. Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. Mol. Pharmacol., 2002, 61, 533-545
17. Bräuner-Osborne H.; Egeberg, J.; Nielsen E.; Madsen, U.; Krogsgaard-Larsen P. Ligands for glutamate receptors: design and thera-peutic prospects. J. Med. Chem., 2000, 43, 2609-2645
18. Chizh, B.A., Headley, P.M. NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses. Curr. Pharm. Des.,2005, 11, 2977-2994.
19. Furukawa, H.; Singh, S.K.; Mancusso, R.; Gouaux, E. Subunitarrangement and function in NMDA receptors. Nature, 2005, 438,185-192.
20. Schorge, S.; Colquhoun, D. Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. J. Neuro- sci., 2003, 23, 1151-1158.
21. Chenard, B.L.; Menniti, F.S. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des., 1999,5, 381-404.
22. Perin-Dureau, F.; Rachline, J.; Neyton, J.; Paoletti, P. Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J. Neurosci., 2002, 22, 5955-5965.
23. Malherbe, P.; Mutel, V.; Broger, C.; Perin-Dureau, F.; Kemp, J.A.;Neyton, J.; Paoletti, P.; Kew, J.N. Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. J. Pharmacol. Exp. Ther., 2003, 307, 897-905.
24. Chizh, B.A.; Headley, P.M. NMDA antagonists and neuropathicpain--multiple drug targets and multiple uses. Curr. Pharm. Des.,2005, 11, 2977-2994.
25. Kemp, J.A.; McKernan, R.M. NMDA receptor pathways as drug targets. Nat. Neurosci., 2002, 5, 1039-1042.
26. Layton, M.E.; Kelly III, M.J.; Rodzinak, K.J. Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. Curr. Top. Med. Chem., 2006, 6, 697-709.
27. Biegon, A.; Gibbs, A.; Alvarado, M.; Ono, M.; Taylor, S. In vitroand in vivo characterization of.[3H]CNS-5161, a use-dependent ligand for the N-methyl-D-aspartate receptor in rat brain. Synapse,2007, 61, 577-586.
28. Sakurai, S.; Penney, J.; Young, A. Regionally distinct N-methyl-D-aspartate receptors distinguished by quantitative autoradiography of[3H]MK-801 binding in rat brain. Neurochem., 1993, 60, 1344-1353.
29. Rigby, M.; Le Bourdellès, B.; Heavens, R.P.; Kelly, S.; Smith, D.;Butler, A.; Hammans, R.; Hills, R.; Xuereb, J.H.; Hill, R.G.; Whiting, P.J.; Sirinathsinghji, D.J. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience, 1996, 73, 429-447.
30. Wee, K.S.; Zhang, Y.; Khanna, S.; Low, C.M. Immunolocalization of NMDA receptor subunit NR3B in selected structures in the ratforebrain, cerebellum, and lumbar spinal cord. J. Comp. Neurol.2008, 509, 118-135.
31. Eriksson, M.; Nilsson, A.; Samuelsson, H.; Samuelsson, E.B.; Mo, L.; Akesson, E.; Benedikz, E.; Sundström, E. On the role of NR3A in human NMDA receptors. Physiol. Behav., 2007, 92, 54-59
32. Waterhouse, R. Imaging the PCP site of the NMDA ion channel.Nucl. Med. Biol., 2003, 30, 869-78.
33. Haradahira, T.; Sasaki, S.; Maeda, M.; Kobayashi, K.; Inoue, O.;Tomita, U.; Nishikawa, T.; Suzuki, K. Synthesis and brain distribution of carbon 11 labeled analogs of antagonists for the NMDA receptor coupled PCP-binding sites. J. Label. Compd. Radiopharm.,1998, 41, 843-58.
34. Ponchant, M.; Kamenka, J.M.; Crouzel, C. Synthesis of 3-[18F]fluoromethyl-TCP, a potential tool for PET study of the NMDA receptor channel complex. J. Label. Compd. Radiopharm.,1992, 31, 955-960.
35. Maeda, M.; Tsukiyama, S.; Fukumura, T.; Orita, K.; Kojima, M.Positron labeled analogs of TCP: Synthesis of 1-[4-[18F]fluoromethyl-1-(2-thienyl)cyclohexyl]piperidine. Appl.Radiat.Isot., 1991, 42, 563-570.
36. Ponchant, M.; Crouzel, C.; Kamenka, J.M.; Pappata, S. Synthesis of a new analog of TCP,.[18F]3-fluoromethyl-TCP: a potent ligand for the NMDA glutamatergic receptor. J. Label. Compd. Radiopharm., 1993, 22, 255-256.
37. Chaudieu, I.; Vignon, J.; Chicheportiche, M.; Kamenka, J.M.;Trouiller, G.; Chicheportiche, R. Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs. Pharmacol. Biochem. Behav., 1989, 32, 699-705
38. Kiesewetter, D.O.; Rice, K.C.; Matson, M.; Finn, R. Radiochemical synthesis of[18F]fluorothienylcyclohexylpiperidine ([18F]FTCP). J. Label. Compd. Radiopharm., 1989, 27, 277-286.
39. Ferrarese, C.; Guidotti, A.; Costa, E.; Miletich, R.S.; Rice, K.C.; de Costa, B.R.; Fulham, M.J.; Di, C. In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine, a possible ligand for positron emission tomography. Neuropharmacology, 1991, 30, 899-905.
40. Kilbourn, M.R.; Mathis, C.A. Discussion of targeting proteins invivo: in vitro guidelines. Nucl. Med. Biol., 2006, 33, 449-451
41. Ouyang, X.; Mukherjee, J.; Yang, Z.Y. Synthesis, radiosynthesis, and biological evaluation of fluorinated thienylcyclohexyl piperidine derivatives as potential radiotracers for the NMDA receptor-linked calcium ionophore. Nucl. Med. Biol., 1996, 23, 315-324.
42. Orita, K.; Sasaki, S.; Maeda, M.; Hashimoto, A.; Nishikawa, T.;Yugami, T.; Umezu, K. Synthesis and evaluation of 1-(1-[5-(2'[18F]fluoroethyl)-2-thienyl]cyclohexyl)piperidine as a potential in vivo radioligand for the NMDA receptor-channel complex. Nucl.Med. Biol., 1993, 20, 865-873.
43. Shibayama, Y.; Sasaki, S.; Tomita, U.; Nishikawa, T.; Maeda, M.Synthesis and evaluation of new 18F-labelled thienylcyclo-hexylpiperidine (TCP) analogues as radioligands for the NMDA receptor-channel complex. J. Label. Compd. Radiopharm., 1996,38, 77-86.
44. Keana, J.F.W.; Scherz, M.W.; Quarum, M.; Sonders, M.S.; Weber,E. Synthesis and characterization of a radiolabelled derivative of the phencyclidine/N-methyl-D-aspartate receptor ligand (+)-MK-801 with high specific radioactivity. Life Sci., 1988, 43, 965-973.
45. Kiesewetter, D.O.; Finn, R.D.; Rice, K.C.; Monn, J.A. Synthesis of11 C-labeled (±)-5-methyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine. [(±)- [11C]MK801]. Int. J. Rad. Appl. Instrum. A,1990, 41, 139-142.
46. Andersson, Y.; Tyrefors, N.; Sihver, S.; Onoe, H.; Watanabe, Y.;Tsukada, H.; Langstrom, B. Synthesis of a 11C-labelled derivative of the N-methyl-D-aspartate receptor antagonist MK-801. J. Label.Compd. Radiopharm., 1998, 41, 567-571.
47. Sihver, S.; Sihver, W.; Andersson, Y.; Murata, T.; Bergstrom, M.;Onoe, H.; Matsumura, K.; Tsukada, H.; Oreland, L.; Langstrom, B.; Watanabe, Y. In vitro and in vivo characterization of (+)-3- [11C]cyano-dizocilpine. J. Neural. Transm., 1998, 105, 117-131
48. Wieland, D.; Kilbourn, M.; Yang, D.J.; Laborde, E.; Gildersleeve, D.; Van Dort, M.; Pirat, J.; Ciliax, G.; Young, A. NMDA Receptor channels. Labelling of MK-801 with iodine-125 and fluorine-18. Appl. Radiat. Isot., 1988, 39, 1219-1225.
49. Denis, A.; Crouzel, C. Synthesis and labelling with 18F of an MK801 analogue,.[18F]-5-(fluoroethyl)-10,11-dihydro-5H-dibenzocy-cloheptene-5,10-imine. J. Label. Compd. Radiopharm., 1989, 27,1003-1013.
50. Gibson, E.G.; Burns, H.D.; Thorpe, H.H.; Eng, W.S.; Ransom, R.Salomon, H. In vivo binding and autoradiographic imaging of (+) 3- [125I]MK-801 to the NMDA receptor-channel complex in rat brain. Int. J. Rad. Appl.Instrum B, 1992, 19, 319-326
51. Yang, D.J.; Ciliax, B.J.; Van Dort, M.E.; Gildersleeve, D.; Pirat, J.L.; Young, A.B.; Wieland, D.M. Synthesis and receptor binding studies of (±)1-iodo-MK-801. Pharm. Res., 1989, 6, 474-476
52. Ransom, R.W.; Eng, W.S.; Burns, H.D.; Gibson, R.E.; Solomon,H.F. (+)-3- [123I]Iodo-MK-801, synthesis and characterization of binding to the N-methyl-D-aspartate receptor complex. Life Sci.,1990, 46, 1103-10.
53. Rung, J.P.; Carlsson, A.; Markinhuhta, R.K.; Carlsson, M.L. (+)-MK-801 induced social withdrawal in rats, a model for negative symptoms of schizophrenia. Prog. Neuropsychopharmacol. Biol.Psychiatry, 2005, 29, 827-832.
54. Blin, J.; Denis, A.; Yamaguchi, T.; Crouzel, C.; MacKenzie, E.T.;Baron, J.C. PET studies of. [18F]methyl-MK-801, a potential NMDA receptor complex radioligand. Neurosci. Lett., 1991, 121,183-186.
55. Jacobson, W.; Cottrell, G.A. Rapid visualization of NMDA receptors in the brain: characterization of (+)-3- [125I]-iodo-MK-801 binding to thin sections of rat brain. J Neurosci. Methods, 1993, 46; 17-25.
56. Owens, J.; Wyper, D.J.; Patterson, J.; Brown, D.R.; Elliott, A.T.;Teasdale, G.M.; McCulloch J. First SPET images of glutamate(NMDA) receptor activation in vivo in cerebral ischaemia. Nucl.Med. Commun., 1997, 18, 149-158.
57. Brown, D.R.; Wyper, D.J.; Owens, J.; Patterson, J.; Kelly, R.C.; Hunter, R.; McCulloch, J. 123Iodo-MK-801, a SPECT agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease. J. Psychiatr. Res., 1997, 31, 605-19
58. Ishibashi, N.; Kuwamura, T.; Sano, H.; Yamamoto, F.; Haradahira, T.; Suzuki, K.; Suhara, T.; Sasaki, S.; Maeda, M. Synthesis and evaluation of 18F- and 11C-labelled 9,10-ethanobenzo [b]quinoli-zinium derivatives for imaging of the NMDA receptor at the TCP-binding site. J. Label. Compd. Radiopharm., 2000, 43, 375-383
59. Sasaki, S.; Kanda, T.; Ishibashi, N.; Yamamoto, F.;Haradahira, T.;Okauchi, T.; Meda, J. Suzuki, M.; Maeda, M. 4,5,9,10-Tetrahydro-1,4-ethanobenz [b]quinolizine as a prodrug for its quinoliziniumcation as a ligand to the open state of the TCP-binding site ofNMDA receptors. Bioorg. Med. Chem. Lett., 2001, 11, 519-521
60. Hu, L.Y.; Guo, J.; Magar, S.S.; Fischer, J.B.; Burke-Howie, K.J.;Durant, G.J. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers. J. Med. Chem., 1997, 40, 4281-4289.
61. Waterhouse, R.N.; Dumont, F.; Sultana, A.; Simpson, N.; Laruelle,M. Synthesis of. [11C]-N-(2-chloro-5-thiomethylphenyl)-N-(3-methoxyphenyl)-N-methylguanidine ([11C]GMOM), a candidatePET tracer for imaging the PCP site of the NMDA ion channel.J.Label. Compd. Radiopharm., 2002, 45, 955-964.
62. Waterhouse, R.N.; Slifstein, M.; Dumont, F.; Zhao, J.; Chang, RC.;Sudo, Y.; Sultana,A.;Balter,A.;Laruelle,M.Invivoevaluationof[11C]N-(2-chloro-5-thiomethylphenyl)-N'-(3-methoxy-phenyl)-N'-methylguanidine ([11C]GMOM) as a potential PET radiotracer forthe PCP/NMDA receptor. Nucl. Med. Biol., 2004, 31, 939-948.
63. Dumont, F.; Sultana, A.; Waterhouse, R.N. Synthesis and in vitroevaluation of N,N'-diphenyl and N-naphthyl-N'-phenylguanidinesas N-methyl-D-aspartate receptor ion-channel ligands. Bioorg.Med. Chem. Lett., 2002, 12, 1583-1586.
64. Walters, M.R.; Bradford, A.P.J.; Fischer, J.; Lees, K.R. Early clini-cal experience with the novel NMDA receptor antagonist CNS5161. Br. J. Clin. Pharmacol., 2002, 53, 305-311.
65. Zhao, Y.; Robins, E.; Turton, D.; Brady, F.; Luthra, S.; Arstad, E.Synthesis and characterization of N-(2-chloro-5-methylthiophenyl)-N-(3-methylthiophenyl)-N- [11C]methylguanidine. [11C]CNS 5161, acandidate PET tracer for functional imaging of NMDA receptors. J.Label. Compd. Radiopharm., 2006, 49,163-170.
66. Asselin, M.C.; Hammer, A.; Turton, D.; Osman, S.; Koepp, M.;Brooks, D. Initial kinetic analysis of the in vivo binding of the puta-tive NMDA receptor ligand. [11C]CNS 5161 in humans. NeuroI-mage, 2004, 22, T137.
67. Hammers, A.; Asselin, M.C.; Brooks, D.J.; Luthra, K.; Hume, S.P.;Thompson, P.J; Turton, D.R.; Duncan, J.S.; Koepp, M.J. Correlation of memory function with binding of.[11C]CNS 5161, a novelputative NMDA ion channel PET ligand. NeuroImage, 2004, 22,T54.
68. Owens, J.; Tebbutt, A.A.; Kodal, A.M.; Magar, S.S.; Perlman, M.E.; Robins, D.J.; Durant, G.J.; McCulloch, J. Synthesis andbinding characteristics of N-(1-Naphtyl)-N'-(3- [125I]iodophenyl)-N'methylguanidine ([125I]CNS 1261), a potential SPECT agent forimaging NMDA receptor activation. Nucl. Med. Biol., 2000, 27,557-564.
69. Knol, R.J.; De Bruin, K.; Van Eck-Smit, B.; Pimlott, S.; Wyper, D.J.; Booij, J. In vivo. [123I] binding to D-serine-activated andMK801-blocked NMDA receptors, a storage phosphor imagingstudy in rat. Synapse, 2009, 67, 557-564.
70. Erlandsson, K.; Bressan, R.A.; Mulligan, R.S.; Gunn, R.N.; Cun-ningham, V.J.; Owens, J.; Wyper, D.; Ell, P.J.; Pilowski, L.S. Ki-netic modelling of. [123I]CNS 1261- a potential SPET tracer for theNMDA receptor. Nucl. Med. Biol., 2003, 30, 441-454.
71. Bressan, R.A.; Erlandson, K.; Mulligan, R.S.; Gunn, R.N.; Cun-ningham, V.J.; Owens, J.; Cullum, I.D.; Ell, P.J.; Pilowski, L.S. Abolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. Nucl. Med. Biol., 2004, 31, 155-164.
72. Stone, J.M.; Erlandsson, K.; Arstad, E.; Bressan, R.A.; Squassante, L.; Teneggi, V.; Ell, P.J.; Pilowski, L.S. Ketamine displaces thenovel NMDA receptor SPET probe. [123I]CNS-1261 in humans invivo. Nucl. Med. Biol., 2006, 33, 239-243.
73. Bressan, R.A.; Erlandson, K.; Stone, J.M.; Mulligan, R.S.; Krystal, J.H.; Ell, P.J.; Pilowski, L.S. Impact of schizophrenia and chronicantipsychotic treatment on. [123I]CNS 1261 binding o N-methyl-D-aspartate receptor in vivo. Biol. Psychiatry, 2005, 58, 41-46.
74. Stone, J.M.; Erlandsson, K.; Arstad, E.; Squassante, L.; Teneggi, V.; Bressan, R.A.; Krystal, J.H.; Ell, P.J.; Pilowski, L.S. Relation-ship between ketamine-induced psychotic symptoms and MDAreceptor occupancy - a. [123I]CNS-1261 SPET study. Psychophar-macology, 2008, 197, 401-408.
75. Stone, J.M. Imaging the glutamate system in humans, relevance todrug discovery for schizophrenia. Curr. Pharm. Des., 2009, 15,2594-2602.
76. Amokhtari, M.; Deryvenko, E.; Gourand, F.; Sobrio, F.; Barré, L.Synthesis of two substituted guanidines as radioligands for NMDAreceptors studies. J. Label. Compd. Radiopharm., 1999, 42, S622-623.
77. Lodge, D.; Johnsson, K. Noncompetitive excitatory amino acidreceptor antagonists. Trends Pharmacol. Sci., 1990, 11, 81-86.
78. Smith, D.J.; Bouchal, R.L.; DeSanctis, C.A.; Monroe, P.J.; Ame-dro, J.B.; Perrotti, J.M.; Crisp, T. Properties of the interaction be-tween ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology, 1987, 26, 1253-1260.
79. Hartvig, P.; Valtysson, J.; Antoni, G.; Westerberg, G.; Langstrom, B.; Ratti, M.E.; Oye, I. Brain kinetics of (R)- and (S)- [N-methyl-11 C]ketamine in the rhesus monkey studied by positron emissiontomography (PET). Nucl. Med. Biol., 1994, 21, 927-934.
80. Shiue, C.Y.; Vallabhahosula, S.; Wolf, A.P.; Dewey, S.L.; Fowler, J.S.; Schlyer, D.J.; Arnett, C.D.; Zhou, Y.G. Carbon-11 labelledketamine-synthesis, distribution in mice and PET studies in ba-boons. Nucl. Med. Biol., 1997, 24, 145-150.
81. Hartvig, P.; Valtysson, J.; Lindner, K.J.; Kristensen, J.; Karlsten, R.; Gustafsson, L.L.; Persson, J.; Svensson, J.O.; Oye, I.; Antoni, G. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measuredwith positron emission tomography in healthy volunteers. Clin.Pharmacol. Ther., 1995, 58, 165-173.
82. Kumlien, E.; Hartvig, P.; Valind, S.; Oye, I.; Tedroff, J.; Lang-strom, B. NMDA-receptor activity visualized with (S)-[N-methyl-11 C]ketamine and positron emission tomography in patients withmedial temporal lobe epilepsy. Epilepsia, 1999, 40, 30-37.
83. Robinson, D.M.; Keating, G. Memantine, a review of its use inAlzheimer's disease. Drugs, 2006, 66, 1515-1534.
84. Samnick, S.; Ametamey, S.; Gold, M.; Schubiger, P. Synthesis andpreliminary in vitro evaluation of a new memantine derivative 1-amino-3-[18F]fluoromethyl-5-methyl-adamantane: A potential ligandfor mapping the N-methyl-D-aspartate receptor complex. J. Label.Compd. Radiopharm., 1997, 39, 241-250.
85. Ametamey, S.M.; Samnick, S.; Leenders, K.L.; Vontobel, P.;Quack, G.; Parsons, C.G.; Schubiger, P.A. Fluorine-18 radiolabel-ling, biodistribution studies and preliminary PET evaluation of anew memantine derivative for imaging the NMDA receptor. J. Re-cept. Signal Transduct. Res., 1999, 19, 129-141.
86. Samnick, S.; Ametamey, S.; Leenders, K.L.; Vontobel, P.; Quack, G.; Parsons, C.G.; Neu, H.; Schubiger, P.A. Electrophysiologicalstudy, biodistribution in mice, and preliminary PET evaluation in arhesus monkey of 1-amino-3- [18F]fluoromethyl-5-methyl-adaman-tane (18F-MEM), a potential radioligand for mapping the NMDA-receptor complex. Nucl. Med. Biol., 1998, 25, 323-330.
87. Ametamey, S.M.; Bruehlmeier, M.; Kneifel, S.; Kokic, M.; Honer, M.; Arigoni, M.; Buck, C.; Sammick, S.; Quack, G.; Schubiger, P.PET studies of 18F-memantine in healthy volunteers. Nucl. Med.Biol., 2002, 29, 227-231.
88. Rammes, G.; Danysz, W.; Parsons, C.G. Pharmamacodynamics ofmemantine, an update. Curr. Neuropharmacol., 2008, 6, 55-78.
89. Grauert, M.; Rho, J.M.; Subramaniam, S.; Rogawski, M.A. N-methyl-D-aspartate receptor channel block by the enantiomer 6,7-benzomorphans BIII 277 CL and BIII 281 CL. J. Pharmacol. Exp.Ther., 1998, 285, 767-776.
90. Kokic, M.; Honer, M.; Kessler, L.J.; Grauert, M.; Schubiger, P.A.;Ametamey, S.M. Synthesis and in vitro and in vivo evaluation of [11C]methyl-BIII277CL for imaging the PCP-binding site of theNMDA receptor by PET. J. Recept. Signal Transduct. Res., 2002,22, 123-139.
91. Fuchigami, T.; Haradahira, T.; Arai, T.; Okauchi, T.; Maeda, J.;Susuki, K.; Yamamoto, F.; Sasaki, S.; Maeda, M. Synthesis andbrain regional distribution of. [11C]NPS 1506 in mice and rat, an N-methyl-D-aspartate (NMDA) receptor antagonist. Biol. Pharm.Bull., 2003, 26, 1570-1573.
92. Morris, H.; Luthra, S.K.; Brown, D.; MacLeod, A.; Brady, F. Syn-thesis of. [11C]-L-703,717, a potential ligand for PET studies of theglycine site of the NMDA receptor. J. Label. Compd. Radiopharm.,1997, 40, 640-641.
93. Haradahira, T.; Suzuki, K. An improved synthesis of. [11C]L-703,717 as a radioligand for the glycine site of the NMDA recep-tor. Nucl. Med. Biol., 1999, 26, 245-247.
94. Opacka-Juffery, J.; Morris, H.; Ashworth, S.; Osman, S.; Hirani, E.; Macleod, A.M.; Luthra, S.K.; Hume, S.P. In,Quantitative Func-tional Brain Imaging with PET; Carson, R.E.; Daube-Witherspoon,M.; Herscovitch, P. Ed.; Academic Press: San Diego, 1998; pp.299-303.
95. Haradahira, T.; Zhang, M.R.; Maeda, J.; Okauchi, T.; Kawabe, K.;Kida, T.; Suzuki, K.; Suhara, T. A strategy for increasing the brainuptake of a radioligand in animals: use of a drug that inhibitsplasma protein binding. Nucl. Med. Biol., 2000, 27, 357-360.
96. Haradahira, T.; Okauchi, T.; Maeda, J.; Zhang, M.R.; Kida, T.;Kawabe, K.; Mishina, M.; Watanabe, Y.; Suzuki, K.; Suhara, T. Apositron-emitter labeled glycine(B) site antagonist,.[11C]L-703,717,preferentially binds to a cerebellar NMDA receptor subtype con-sisting of GluR epsilon3 subunit in vivo, but not in vitro. Synapse,2002, 43, 131-133.
97. Haradahira, T.; Okauchi, T.; Maeda, J.; Zhang, M.R.; Nishikawa, T.; Konno, R.; Suzuki, K.; Suhara, T. Effects of endogenous ago-nists, glycine and D-serine, on in vivo specific binding of.[11C]L-703,717, a PET radioligand for the glycine-binding site of NMDAreceptors. Synapse, 2003, 50, 130-136.
98. Haradahira, T.; Zhang, M.R.; Maeda, J.; Okauchi, T.; Kida, T.;Kawabe, K.; Sasaki, S.; Suhara, T.; Suzuki, K. A prodrug ofNMDA/glycine site antagonist, L-703,717, with improved BBBpermeability, 4-acetoxy derivative and its positron-emitter labeledanalog. Chem. Pharm. Bull., 2001, 49, 147-150.
99. Matsumoto, R.; Haradahira, T.; Ito, H.; Fujimura, Y.; Seki, C.;Ikoma, Y.; Maeda, J.; Arakawa, R.; Takano, A.; Takahashi, H.; Hi-guchi, M.; Suzuki, K.; Fukui, K.; Suhara, T. Measurement of gly-cine binding site of N-methyl-D-asparate receptors in living humanbrain using 4-acetoxy derivative of L-703,717, 4-acetoxy-7-chloro-3-[3-(4-[11C]methoxybenzyl) phenyl]-2(1H)-quinolone (AcL703)with positron emission tomography. Synapse, 2007, 61, 795-800.
100. Fuchigami, T.; Haradahira, T.; Fujimoto, N.; Nojiri, Y.; Mukai, T.;Yamamoto, F.; Okauchi, T.; Maeda, J.; Suzuki, K.; Suhara, T.;Yamaguchi, H.; Ogawa, M.; Magata Y.; Maeda M. Developmentof N-[11C]methylamino 4-hydroxy-2(1H)-quinolone derivatives asPET radioligands for the glycine-binding site of NMDA receptors.Bioorg. Med. Chem., 2009, 17, 5665-5675.
101. Fuchigami, T.; Haradahira, T.; Fujimoto, N.; Okauchi, T.; Maeda, J.; Suzuki, K.; Suhara, T.; Yamamoto, F.; Sasaki, S.; Mukai, T.;Yamaguchi, H.; Ogawa, M.; Magat, Y.; Maeda, M. Difference inbrain distributions of carbon-11 labeled 4-hydroxy-2(1H)-quinolones as PET radioligands for the glycine-binding site of theNMDA ion channel. Nucl. Med. Biol., 2008, 35, 203-212.
102. Haradahira, T.; Suhara, S.; Okauchi, T.; Maeda, J.; Arai, T.; Sasaki, S. Developments of PET radioligands for NMDA receptors. WorldJ. Nucl. Med., 2002, 1, S183-184.
103. Woodward, R.M.; Huetter, J.E.; Guastella, J.; Keana, J.F.; Weber, E. In vitro pharmacology of ACEA-1021 and ACEA-1031: sys-temically active quinoxalinediones with high affinity and selectiv-ity for N-methyl-D-aspartate receptor glycine sites. Mol. Pharma-col., 1995, 47, 568-581.
104. Keana, J.F.W.; Kher, S.M.; Cai, S.X.; Dinsmore, C.M.; Glenn, A.G.; Guastella, J.; Huang, J.H.; Ilyin, V.; Lü, Y.; Mouser, P.L.;Woodward, R.M.; Weber, E. Synthesis and structure-activity rela-tionships of substituted 1,4-dihydroquinoxaline-2,3-diones, antago-nists of N-methyl-D-aspartate (NMDA) receptor glycine sites andnon-NMDA glutamate receptors. J. Med. Chem., 1995, 38, 4367-4379.
105. Thorell, J.; Stone-Elander, S.; Duelfer, T.; Cai, S.; Jones, L.; Pfef-ferkorn, H.; Ciszewska, G. Synthesis of a 11C-labelled nitrated 1,4-dihydroquinoxaline-2,3-dione, the NMDA glycine receptor antago-nist ACEA 1021 (Licostinel). J. Label. Compd. Radiopharm.,1998, 41, 345-353.
106. [106] Ametamey, S.M.; Kokic, M.; Carrey-Rémy, N.; Bläuenstein, P.;Willman, M.; Bischoff, S.; Schmutz, M.; Schubiger, P.A.; Auber-son, Y.P. Synthesis, radiolabelling and biological characterizationof (D)-7-iodo-N-(1-phosphonoethyl)-5-aminomethylquinoxaline-2,3-dione, a glycine-binding site antagonist of NMDA receptors.Bioorg. Med. Chem. Lett., 2000, 10, 75-78.
107. Westerberg, G.; Carr, R.M.; Langstrom, B.; Sutherland, D. Synthe-sis of (E)-3-[2-([1-11C]phenylcarbamoyl)ethenyl]-4-6-dichloro-indole-2-carboxylic acid ([11C]GV150526X)- a glycine antagonistfor the NMDA-receptor complex. J. Label. Compd. Radiopharm.,1997, 48, 656-657.
108. Waterhouse, R.N.; Sultana, A.; Laruelle, M. In vivo evaluation of[11C]-3-[2-[-(3-methoxyphenylamino)carbonyl]ethenyl]-4,6-dichloroindole-2-carboxylic acid ([11C]3MPICA) as a PET ra-diotracer for the glycine site of the NMDA ion channel. Nucl. Med.Biol., 2002, 29, 791-794.
109. Galea, H.; Ponchant, M.; Bottlaender, M.; Coulon, C.; Fuseau, C.;Loc'h, C.; Crouzel, C. Synthesis of.[76Br]RPR 104632 for in vivostudies of the NMDA receptor channel complex. J. Label. Compd.Radiopharm., 1997, 40, 608-610.
110. Piel, M.; Schirrmacher, R.; Höhnemann, S.; Halmkens, W.; Khol, B.; Jansen, M.; Schmitt, U.; Lüddens, H.; Dannhardt, G.; Rösch, F.Synthesis and evaluation of5,7-dichloro-4-(3-{4-[4-2-[18F]fluoro-ethyl)-piperazine-1-yl]-phenyl}-ureido-1,2,3,4-tetrahydroquinoline-2-carboxylic acid as a potential NMDA ligand to study glutamater-gic neurotransmission in vivo. J. Label. Compd. Radiopharm.,2003, 46, 645-659.
111. Dumont, F.; Slegers, G. Synthesis and in vivo evaluation of 7-chloro-5-[123I]iodo-4-oxo-1,4-dihydroquinoline-2-carboxylic acid.Appl. Radiat. Isot., 1997, 48, 1173-1177.
112. Lynch, D.R.; Guttmann, R.P. NMDA receptor pharmacology:Perspectives from molecular biology. Curr. Drug Targets, 2001, 2,215-231.
113. Roger, G.; Lagnel, B.; Besret, L.; Bramoulle, Y.; Coulon, C.; Ot-taviani, M.; Kassiou, M.; Bottlander, M.; Valette, H.; Dollé, F.Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[11C]one, as a potent NR(1A)/2B subtype selective NMDA PET ra-diotracer. Bioorg. Med. Chem., 2003, 11, 5401-5408.
114. Roger, G.; Dollé, F.; De Bruyn, B.; Liu, X.; Besret, L.; Bramoullé, Y.; Coulon, C.; Ottaviani, M.; Bottlander, M.; Valette, H.; Kassiou, M. Radiosynthesis and pharmacological evaluation of.[11C]EMD-95885, a high affinity ligand for NR2B-containing NMDA recep-tors. Bioorg. Med. Chem., 2004, 12, 3229-3237.
115. Labas, R.; Sobrio, F.; Bramoullé, Y.; Hérard, AS.; Guillermier, M.;Hantraye, P.; Dollé, F.; Barré, L. Radiosynthesis of N-[4-(4-fluorobenzyl)piperidin-1yl]-N'-(2-[11C]oxo-1,3-dihydrobenzimidazol-5-yl) oxamide, a NR2B-selective NMDA re-ceptor antagonist. J. Label. Compd. Radiopharm., 2010, 53, 63-67.
116. Haradahira, T.; Maeda, J.; Okauchi, T.; Zhang, M.R.; Hojo, J.;Kida, T.; Arai, T.; Yamamoto, F.; Sasaki, S.; Maeda, M.; Suzuki, M.Suhara, Ttitle typecontributor. Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (/-)threo-1-(4-hydroxyphenyl)-2-4-hydroxy-4-(p-11Cmethoxyphenyl)piperidino-1-propanol, asa PET tracer for NR2B subunit-containing NMDA receptors./title Nucl.Med. Biol., 2002, 29, 517-525.
117. Dollé, F.; Valette, H.; Demphel, S.; Coulon, C.; Ottaviani, M.;Bottlaender, M.; Kassiou, M. Radiosynthesis and in vivo evaluationof.[11C]Ro-647312, a novel NR1/2B subtype selective NMDA re-ceptor. J. Label. Compd. Radiopharm., 2004, 47, 911-90.
118. Clairborne, C.F.; McCauley, J.A.; Libby, B.; Curtis, N.; Diggle, H.;Kulagowski, J.; Michelson, S.; Anderson, K.D.; Claremon, D.;Freidinger, R.; Bednar, R.; Mosser, S.; Gaul, S.; Connolly, T.;Condra, C.; Bednar, B.; Stump, G.; Lynch, J.; Macaulay, A.; Waf-ford, K.; Koblan, K.; Liverton, N. Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem.Lett.,2003, 13, 697-700.
119. Hamill, T.; McCauley, J.; Burns, H. The synthesis of a ben-zamidine-containing NR2B-selective NMDA receptor ligand la-belled with tritium or fluorine-18. J. Label. Compd. Radiopharm.,2005, 48, 1-10
120. Thominiaux, C.; De Bruyn, B.; Bramoullé, Y.; Hinnen, F.; Dem-phel, S.; Valette, H.; Bottlander, M.; Besret, L.; Kassiou, M.; Dollé,F. Radiosynthesis of (E)-N-(2-[11C]methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selectiveNMDA receptor antagonist. Appl. Radiat. Isot., 2006, 64, 348-354.
121. Arstad, E.; Platzer, S.; Berthele, A.; Pilowsky, L.S.; Luthra, S.K.;Wester, H.J.; Henriksen, G. Towards NR2B receptor selective im-aging agents for PET-synthesis and evaluation of N-[11C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and 4-trifluoromethoxyphenylamidine. Bioorg. Med. Chem., 2006, 14,6307-6313.
122. Williams, K.; Zappia, A.M.; Pritchett, D.B.; Shen, Y.M.; Molinioff,P.B. Sensitivity of the N-methyl-D aspartate receptor to polyaminesis controlled by NR2 subunits. Mol. Pharmacol., 1997, 45, 803-809.
123. Sasaki, S.; Kurosaki, F.; Haradahira, T.; Yamamoto, F.; Maeda, J.;Okauchi, T. Synthesis of 11C-labelled bis(phenylalkyl)amines andtheir in vitro and in vivo binding properties in rodent and monkeybrains. Biol Pharm. Bull., 2004, 27, 531-537.
124. Danysz, W.; Parsons, C.G.; Jirgensons, A.; Kauss, V.Amino-alkyl-cyclohexanes as a novel class of uncompetitiveNMDA receptor antagonists. Curr. Pharm. Des., 2002, 8, 835-843.
125. Gielen, M.; Retchless, B.S.; Mony, L.; Johnson, J.W.; Mechanism of differential control of NMDA receptor activity byNR2 subunits. Nature, 2009, 459, 703-708.
126. Solt, K.; Eger II, E.I.; Raines, D.E. Differential modulation ofhuman N-methyl-D-aspartate receptors by structurally diverse gen-eral anesthetics. Anesth. Analg., 2006, 102, 1407-1411.
127. Rammes, G.; Starker, L.K.; Haseneder, R.; Berkmann, J.; Plack, A.; Zieglgänsberger, W.; Ohl, F.; Kochs, E.F.; Blobner, M. Isoflu-rane anaesthesia reversibly improves cognitive function and long-term potentiation (LTP) via an up-regulation in NMDA receptor 2Bsubunit expression. Neuropharmacology, 2009, 56, 626-636.
128. Nikam, S. Meltzer, L. NR2B selective NMDA receptor antago-nists. Curr. Pharm. Des., 2002, 8, 845-855.
129. Borza, I.; Domany, G.F. NR2B selective NMDA antagonists: theevolution of the ifenprodil-type pharmacophore. Curr. Top. Med.Chem., 2006, 6, 687-695.
130. McCauley, J.A. Amide-containing NR2B/NMDA receptor antago-nists. Expert Opin. Ther. Pat., 2006, 16, 863-870.
131. Farkas, S.; Horvath C.; Kolok, S.; Nagy, J.; Fodor, L.; Gere, A.;Orosz, S.; Mako, E.; Barta-Szalai, G.; Domany, G.; Szombathelyi, Z. In vitro pharmacology of RGH-896, a novel NR2B-subtype-selective NMDA antagonist. Inflammopharmacology, 2005, 13,501-592.
132. Nguyen, K.T.; Claiborne, C.F.; McCauley, J.A.; Libby, B.E.;Claremon, D.A.; Bednar, R.A.; Mosser, S.D.; Gaul, S.L.; Connolly, T.M.; Condra, C.L.; Bednar, B.; Stump, G.L.; Lynch, J.J.; Koblan, K.S.; Liverton, N.J. Cyclic benzamidines as orally efficaciousNR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem.Lett., 2007, 17, 3997-4000.
133. Kawai, M.; Sakurada, I.; Morita, A.; Iwamuro, Y.; Ando, K.;Omura, A.; Sakakibara, S.; Masuda, T.; Koike, H.; Honma, T.; Hat-tori, K.; Takashima, T.; Mizuno, K.; Mizutani, M.; Kawamura, M.Structure-activity relationship study of novel NR2B-selective an-tagonists with arylamides to avoid reactive metabolites formation.Bioorg. Med. Chem. Lett., 2007, 17, 5537-5542.
134. Suetake-Koga, S.; Shimazaki, T.; Takamori K.; Chaki, S.; Kanuma, K.; Sekiguchi, Y.; Suzuki, T.; Kikuchi, T.; Matsui, Y.; Honda, T. Invitro and antinociceptive profile of HON0001, an orally activeNMDA receptor NR2B subunit antagonist. Pharmacol. Biochem.Behav., 2006, 84, 134-141.
135. Liverton, N.J.; Bednar, R.A.; Bednar, B.; Butcher, J.W.; Clai-borne, C.F.; Claremon, D.A.; Cunningham, M.; Dilella, A.G.; Gaul, S.L.; Libby, B.E.; Lyle, E.A.; Lynch, J.J.; McCauley, J.A.; Mosser, S.D.; Nguyen, K.T.; Stump, G.I.; Sun, H.; Wang, H.; Yergey, J.;Koblan, K.S. Identification and characterization of 4-methylbenzyl-4-[(pyrimidin-2-lamino)methyl]piperidine-1-carboxylate, an orallybioavailable, brain penetrant NR2B selective N-Methyl-D-Aspartate receptor antagonist. J. Med. Chem., 2007, 50, 807-819.
136. Addy, C.; Assaid, C.; Hreniuk, D.; Stroh, M.; Xu, Y.; Herring, J.;Ellenbogen, A.; Jinnah, H.A.; Kirby, L.; Leibowitz, M.; Stewart, R.M.; Tarsy, D.; Tetrud, J.; Stoch, S.A.; Gottesdiener, K.; Wagner, J. Single-dose administration of MK-0657, an NR2B-selectiveNMDA antagonist, does not result in clinically meaningful im-provement in motor function in patients with moderate Parkinson'sdisease. J. Clin. Pharmacol., 2009, 49, 856-864.
137. Mony, L.; Kew, J.N.C.; Gunthorpe, M.J.; Paoletti, P. Allostericmodulators of NR2B-containing NMDA receptors, molecularmechanisms and therapeutic potential. Br. J. Pharmacol., 2009,157, 1301-1317.